NeoTargets AB
About NeoTargets AB
NeoTargets employs an AI-driven in silico platform to identify selective cancer targets across 140 subtypes, validating them through translational cell models and patient samples to ensure safety and efficacy. This method reduces the risk and cost of drug development while accelerating timelines for targeted therapies in multiple myeloma, glioblastoma, and acute myeloid leukemia.
```xml <problem> The high failure rate of cancer clinical trials, often due to toxicity and inefficacy, stems from inadequate preclinical target assessment and reliance on model systems with limited predictive power. Existing methods lack systematic evaluation of drug targets, leading to the selection of candidates that ultimately fail in clinical studies, wasting resources and delaying effective treatments. </problem> <solution> NeoTargets offers an AI-driven in silico platform to identify and validate selective cancer targets, increasing the probability of success in clinical trials. The platform assesses potential drug targets across 135 cancer subtypes, prioritizing those with optimal characteristics, including "druggability" and selectivity against cancer cells. Candidate targets undergo functional validation using relevant cancer cells, translational cell models for toxicity assessment, well-characterized patient samples (including cancer-initiating cell populations), and patient-derived xenograft (PDX) mouse models. Validated targets are further investigated for mechanisms of action and potential molecular biomarkers. </solution> <features> - Proprietary in silico target assessment tool for identifying cancer-specific and safe targets. - Validation of cancer dependencies in relevant cancer cell lines. - Functional assessment of toxicity in normal healthy cells, including blood cells, cardiomyocytes, hepatocytes, and neurons. - Target validation using primary cancer cells from well-characterized patient samples. - Validation of candidate targets in patient-derived xenograft (PDX) mouse models to assess impact on disease progression and survival rates. - Investigation of molecular mechanisms and predictive markers using functional genomics. - Screening of drug candidates from libraries of small molecule inhibitors, molecular glue degraders, and PROTACs. </features> <target_audience> NeoTargets primarily serves pharmaceutical companies and research institutions focused on developing targeted cancer therapies. </target_audience> <revenue_model> NeoTargets generates revenue through the sale and licensing of validated drug targets and preclinical drugs to established drug companies. </revenue_model> ```
What does NeoTargets AB do?
NeoTargets employs an AI-driven in silico platform to identify selective cancer targets across 140 subtypes, validating them through translational cell models and patient samples to ensure safety and efficacy. This method reduces the risk and cost of drug development while accelerating timelines for targeted therapies in multiple myeloma, glioblastoma, and acute myeloid leukemia.
Where is NeoTargets AB located?
NeoTargets AB is based in Stockholm, Sweden.
When was NeoTargets AB founded?
NeoTargets AB was founded in 2022.
- Location
- Stockholm, Sweden
- Founded
- 2022
- Employees
- 3 employees